2CUREX Stock Overview
Operates as a medtech company in Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
2cureX AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.40 |
| 52 Week High | SEK 2.79 |
| 52 Week Low | SEK 0.20 |
| Beta | 0.63 |
| 1 Month Change | -12.28% |
| 3 Month Change | -36.00% |
| 1 Year Change | -79.33% |
| 3 Year Change | -97.91% |
| 5 Year Change | -97.11% |
| Change since IPO | -95.03% |
Recent News & Updates
Recent updates
We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate
Jun 03
2cureX (STO:2CUREX) Is In A Good Position To Deliver On Growth Plans
Jan 06We're Not Very Worried About 2cureX's (STO:2CUREX) Cash Burn Rate
Sep 23We're Interested To See How 2cureX (STO:2CUREX) Uses Its Cash Hoard To Grow
Jun 02Shareholders Of 2cureX (STO:2CUREX) Must Be Happy With Their 280% Total Return
Feb 18How Does 2cureX's (STO:2CUREX) CEO Salary Compare to Peers?
Nov 29
Shareholder Returns
| 2CUREX | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -7.8% | 0.4% | 0.7% |
| 1Y | -79.3% | -9.4% | 6.3% |
Return vs Industry: 2CUREX underperformed the Swedish Medical Equipment industry which returned -9.4% over the past year.
Return vs Market: 2CUREX underperformed the Swedish Market which returned 6.3% over the past year.
Price Volatility
| 2CUREX volatility | |
|---|---|
| 2CUREX Average Weekly Movement | 17.5% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.5% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: 2CUREX's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: 2CUREX's weekly volatility has decreased from 29% to 18% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 14 | Dan Honeywell | www.2curex.com |
2cureX AB (publ) operates as a medtech company in Europe. The company’s principal product is IndiTreat, an IVD test, which helps to predict cancer patient’s response and resistance to different drugs and select the appropriate treatment. It is also conducting various clinical programs for IndiTreat for colorectal, ovarian, and pancreatic cancers.
2cureX AB (publ) Fundamentals Summary
| 2CUREX fundamental statistics | |
|---|---|
| Market cap | SEK 7.04m |
| Earnings (TTM) | -SEK 26.35m |
| Revenue (TTM) | SEK 1.98m |
3.6x
P/S Ratio-0.3x
P/E RatioIs 2CUREX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2CUREX income statement (TTM) | |
|---|---|
| Revenue | SEK 1.98m |
| Cost of Revenue | SEK 9.61m |
| Gross Profit | -SEK 7.63m |
| Other Expenses | SEK 18.72m |
| Earnings | -SEK 26.35m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | -1.50 |
| Gross Margin | -386.18% |
| Net Profit Margin | -1,333.30% |
| Debt/Equity Ratio | 0% |
How did 2CUREX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 03:07 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
2cureX AB (publ) is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Oscar Bergman | Redeye |